Table 3 Differential metabolites for discrimination between HG BC patients and LG BC patients.
From: Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer
No. | tR(min) | m/za | Formula | Metabolitesb | VIPe | p valuef | FCg | AUCh | sensitivity (%) | specificity (%) |
---|---|---|---|---|---|---|---|---|---|---|
1 | 0.66 | 296.0661 | C8H14N3O7P | 5-Aminoimidazole ribonucleotidec | 1.71 | 1.79 × 10−8 | 1.34 | 0.79(0.68–0.89) | 0.73 | 0.68 |
2 | 1.02 | 137.0457 | C5H4N4O | Hypoxanthined | 1.49 | 2.04 × 10−6 | 1.35 | 0.79(0.67–0.88) | 0.68 | 0.70 |
3 | 1.44 | 269.0880 | C10H12N4O5 | Inosined | 1.72 | 1.34 × 10−8 | 1.44 | 0.86(0.75–0.93) | 0.68 | 0.82 |
4 | 4.83 | 265.1182 | C13H16N2O4 | Acetyl-N-formyl-5-methoxykynurenamined | 1.54 | 8.81 × 10−7 | 1.41 | 0.80(0.69–0.89) | 0.82 | 0.70 |
5 | 5.67 | 304.2112 | C15H29NO5 | 3-hydroxyoctanoyl carnitinec | 1.08 | 9.55 × 10−4 | 0.73 | 0.67(0.55–0.78) | 0.70 | 0.65 |
6 | 6.63 | 176.0697 | C10H9NO2 | Indoleacetic acidd | 1.82 | 1.20 × 10−9 | 1.34 | 0.88(0.77–0.94) | 0.76 | 0.80 |
7 | 6.91 | 332.2428 | C17H33NO5 | 3-hydroxydecanoyl carnitinec | 1.38 | 1.39 × 10−5 | 0.76 | 0.80(0.69–0.89) | 0.76 | 0.73 |
8 | 7.80 | 466.3159 | C26H43NO6 | Glycocholic acidd | 1.19 | 2.64 × 10−4 | 1.39 | 0.77(0.65–0.86) | 0.62 | 0.70 |
9 | 8.09 | 512.3345 | C24H50NO8P | PS(O-18:0/0:0)c | 1.69 | 2.78 × 10−8 | 1.35 | 0.88(0.77–0.94) | 0.73 | 0.82 |
10 | 8.39 | 318.3003 | C18H39NO3 | Phytosphingosined | 1.60 | 2.40 × 10−7 | 1.40 | 0.84(0–.73–0.92) | 0.76 | 0.68 |
11 | 9.23 | 302.3052 | C18H39NO2 | Sphinganined | 1.88 | 1.60 × 10−10 | 1.38 | 0.91(0.81–0.96) | 0.80 | 0.76 |
12 | 9.85 | 422.3263 | C23H45NO4 | linolenyl carnitinec | 1.42 | 8.24 × 10−6 | 1.38 | 0.77(0.65–0.86) | 0.68 | 0.76 |
13 | 13.44 | 552.4028 | C28H58NO7P | LysoPC(20:0)d | 1.39 | 1.22 × 10−5 | 1.34 | 0.76(0.64–0.86) | 0.70 | 0.65 |